In contrast, our study investigated the association between radiographic response (i.e., percent reduction) and pathological assessment of tumor response in patients with advanced HCC who had received combined treatment with a TKI and an anti–PD-1 antibody without locoregional therapy before undergoing hepatectomy. The gene discussed is RPL17; the disease is hepatocellular carcinoma.